Harnessing the power of the immune system to combat disease.
.svg){kind=icon}
.svg){kind=icon}
Unlike conventional emulsions or lipid nanoparticles (LNPs) that leak cargo systemically, DPX is fully synthetic and compatible with peptides, proteins, mRNA, virus-like particles, and small molecules. It's ideal for mRNA delivery—remaining localized at the injection site with superior stability over LNPs.
Maveropepimut-S (MVP-S), our lead clinical asset, has demonstrated a 21% overall response rate and 63% disease control rate in recurrent ovarian cancer. In relapsed/refractory DLBCL, MVP-S plus Keytruda® achieved complete responses in 3 of 6 evaluable patients. Meaning no detectable cancer remained after treatment.
We collaborate with leading institutions and universities and hold exclusive patents in haptenized vaccine technologies and T cell-mediated immune response diagnostics.
%202%20copy%201.svg){kind=icon}
Revolutionizing treatment delivery
.svg){kind=icon}
.svg){kind=icon}
